Unveiling 3 Undiscovered Gems In Sweden With Strong Potential

As global markets experience mixed performances, small-cap stocks continue to outpace their larger counterparts, drawing investor attention. In this dynamic landscape, identifying promising opportunities in underexplored regions like Sweden can be particularly rewarding. A good stock often exhibits strong fundamentals and resilience amidst market fluctuations, making it essential to explore these hidden gems with robust potential in the Swedish market.

Top 10 Undiscovered Gems With Strong Fundamentals In Sweden

Name	Debt To Equity	Revenue Growth	Earnings Growth	Health Rating
Bahnhof	NA	9.47%	15.07%	★★★★★★
Softronic	NA	3.58%	7.41%	★★★★★★
Duni	29.33%	10.78%	22.98%	★★★★★★
AB Traction	NA	5.38%	5.19%	★★★★★★
Firefly	NA	15.31%	29.94%	★★★★★★
Creades	NA	-28.54%	-27.09%	★★★★★★
Linc	NA	56.01%	0.54%	★★★★★★
Rederiaktiebolaget Gotland	NA	-14.29%	18.06%	★★★★★★
AQ Group	7.30%	14.89%	22.26%	★★★★★★
Karnell Group	44.29%	22.04%	39.45%	★★★★★☆

Click here to see the full list of 52 stocks from our Swedish Undiscovered Gems With Strong Fundamentals screener.

Here we highlight a subset of our preferred stocks from the screener.

Betsson (OM:BETS B)

Simply Wall St Value Rating: ★★★★★★

Overview: Betsson AB (publ) is a company that invests in and manages online gaming businesses across various regions including the Nordic countries, Latin America, Western Europe, Central and Eastern Europe, Central Asia, and internationally; it has a market cap of approximately SEK17.58 billion.

Operations: The company's primary revenue stream is from Casinos & Resorts, generating €1009.20 million.

Betsson, a notable player in the gaming industry, has shown robust financial health. The company’s debt to equity ratio improved from 25.9% to 21.7% over five years, reflecting prudent financial management. Trading at 74.6% below its estimated fair value, Betsson offers significant potential for investors looking for undervalued stocks. Recent earnings growth of 12.2%, surpassing the hospitality industry’s -12.7%, underscores its strong market position and promising future prospects with forecasted annual earnings growth of 14.78%.

• Click here to discover the nuances of Betsson with our detailed analytical health report.

• Gain insights into Betsson's past trends and performance with our Past report.

Biotage (OM:BIOT)

Simply Wall St Value Rating: ★★★★★★

Overview: Biotage AB (publ) offers solutions and products for drug discovery and development, analytical testing, and water and environmental testing, with a market cap of SEK15.57 billion.

Operations: Biotage generates revenue primarily from its Healthcare Software segment, which contributed SEK 2.08 billion. The company has a market cap of SEK 15.57 billion.

Biotage, a Swedish life sciences firm, has demonstrated notable financial health and growth. The company's debt to equity ratio improved from 19.2% to 4% over the past five years, reflecting prudent financial management. Recent earnings for Q2 2024 showed sales of SEK 504 million and net income of SEK 48 million, up from SEK 409 million and SEK 34 million respectively in the same period last year. Biotage's earnings grew by 16.2%, outperforming the Life Sciences industry average of -13%. Additionally, it trades at a significant discount—46% below estimated fair value—making it an attractive prospect for investors seeking undervalued opportunities in Sweden's market landscape.

• Dive into the specifics of Biotage here with our thorough health report.

• Gain insights into Biotage's historical performance by reviewing our past performance report.

MedCap (OM:MCAP)

Simply Wall St Value Rating: ★★★★★★

Overview: MedCap AB (publ) is a private equity firm focusing on secondary direct investments, later stage ventures, industry consolidations, add-on acquisitions, growth capital, middle market opportunities, mature businesses, turnarounds and buyouts with a market cap of SEK8.50 billion.

Operations: MedCap generates revenue primarily from Specialist Drugs (SEK469.30 million) and Medicine - Technology (SEK579.30 million), with a Segment Adjustment of SEK692.10 million.

MedCap's earnings surged by 43.7% over the past year, outperforming the Life Sciences industry, which saw a -13% change. Trading at 44.1% below its estimated fair value, MedCap seems undervalued. The company's debt to equity ratio has improved from 43.6% to 8.2% over five years, indicating strong financial health. Recent earnings reports show net income increased to SEK 56 million in Q1 and SEK 56.8 million in Q2 of 2024 compared to previous periods.

• Get an in-depth perspective on MedCap's performance by reading our health report here.

• Learn about MedCap's historical performance.

Where To Now?

• Embark on your investment journey to our 52 Swedish Undiscovered Gems With Strong Fundamentals selection here.
• Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
• Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Seeking Other Investments?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com